Table 3.
Univariable and multivariable analyses for OS.
| Variable | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|
| HR | 95% CIs | p-Value | HR | 95% CIs | p-Value | |
| Age ≤ 50 years (ref. > 50 years) | 0.812 | 0.375–1.757 | 0.597 | |||
| TP53 mutation (ref. TP53 wild-type) | 3.092 | 1.427–6.698 | 0.004 | 2.488 | 1.407–3.788 | 0.044 |
| Histologic grade III (ref. HG I-II) | 0.909 | 0.405–2.038 | 0.816 | |||
| HR positive (ref. HR negative) # | 0.549 | 0.244–1.238 | 0.148 | |||
| HER2 positive (ref. HER2 negative) | 1.017 | 0.442–2.339 | 0.968 | |||
| LVI present (ref. LVI absent) # | 2.604 | 1.686–4.021 | <0.001 | 2.366 | 1.495–3.747 | <0.001 |
| Ki67 high (≥ 20%) (ref. Ki67 < 20%) | 2.419 | 1.096–5.340 | 0.029 | 2.35 | 0.966–5.717 | 0.06 |
| Tumor > 2 cm (ref. Tumor ≤ 2 cm) * | 2.781 | 1.079–7.170 | 0.034 | 2.061 | 0.765–5.551 | 0.153 |
| Nodal involvement (ref. Node-negative) * | 1.69 | 0.718–3.980 | 0.23 | |||
| BCS (ref. Mastectomy) | 0.927 | 0.413–2.085 | 0.855 | |||
| HER2-targeted therapy (ref. no treatment) | 0.914 | 0.367–2.276 | 0.846 | |||
# Patients without definite data were excluded. * Patients who underwent neoadjuvant chemotherapy were excluded. Abbreviations, OS; overall survival, HR, hazard ratio, CIs; confidence intervals, HR, hormone receptor, HER2; human epidermal growth factor receptor 2, LVI; lymphovascular invasion, BCS; breast-conserving surgery.